News on Amarin (NAS: AMRN) has stalled recently while everyone holds their breath and waits for the Food and Drug Administration ,to decide whether to grant the company's triglyceride-lowering drug, Vascepa, new chemical entity (or NCE) status. The NCE designation would mean market exclusivity for five years, and obtaining this would also be a major driving force for the company's stock price. However, shareholders have to remember that the FDA has still not made a final decision. In this video, health care analysts Max Macaluso and David Williamson discuss the best- and worst-case scenarios for Amarin investors in the short term.
The biotech space can make or break investors overnight, and while Amarin certainly won't go under if it doesn't receive NCE status for Vascepa, the success of the drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article A Must-See Look at Amarin's Best- and Worst-Case Scenarios originally appeared on Fool.com.David Williamson owns shares of Amarin plc (ADR). Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.